Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Eli Lilly and Co LLY

Healthcare Drug Manufacturers - Major
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin... see more

Recent & Breaking News (NYSE:LLY)

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company's Directors and Officers for Breach of Fiduciary Duties - LLY

Business Wire February 5, 2026

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company's Directors and Officers for Breach of Fiduciary Duties - LLY

Business Wire January 22, 2026

Lilly to participate in J.P. Morgan Healthcare Conference

PR Newswire December 16, 2025

Updated data for Lilly's Inluriyo(TM) (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

PR Newswire December 12, 2025

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

PR Newswire December 11, 2025

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

PR Newswire December 9, 2025

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

PR Newswire December 9, 2025

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL

PR Newswire December 9, 2025

Lilly declares first-quarter 2026 dividend

PR Newswire December 8, 2025

Carolyn Bertozzi returns to Lilly board of directors

PR Newswire December 8, 2025

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

PR Newswire December 7, 2025

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

PR Newswire December 3, 2025

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium

PR Newswire November 24, 2025

Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting

PR Newswire November 24, 2025

Lilly announces plans to open Lilly Gateway Labs site in Philadelphia

PR Newswire November 19, 2025

Lilly to participate in Citi's 2025 Global Healthcare Conference

PR Newswire November 18, 2025

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'

PR Newswire November 10, 2025

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

PR Newswire November 6, 2025

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

PR Newswire November 6, 2025

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

PR Newswire November 6, 2025

Podcasts